Ohio Clinical Trials Report — April 2026

For Ohioans considering participation in medical research, April 2026 brings a critical window of opportunity, especially for those looking to join studies that are nearing their enrollment deadlines. Across the state, 242 clinical trials are slated to close within the next 90 days. This urgency extends to healthy volunteers, with 27 of these rapidly closing studies actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on specific types of cancer, neurological conditions, and metabolic disorders are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Advanced solid tumor
• Asthma
• Major depressive disorder
• Breast cancer
• Obesity
• Epilepsy
• Idiopathic hypersomnia
• Glioblastoma multiforme
• Ewing sarcoma
• Head and neck squamous cell carcinoma

Major Breakthroughs on the Horizon: Notable New Trials in Ohio

This month, Ohio saw the launch of 21 new clinical trials, offering fresh avenues for participation in cutting-edge research. While this number is a decrease from the 44 trials that opened in March 2026, the new studies include several significant Phase 2 and Phase 3 trials from major sponsors, addressing critical health challenges from cancer to metabolic disorders.

• Incyte Corporation is sponsoring NCT07522073, a Phase 3 study evaluating chemotherapy with or without INCB161734 in previously untreated, KRAS G12D-Mutated metastatic pancreatic ductal adenocarcinoma. This important oncology trial aims to enroll 588 participants to assess the efficacy and safety of this treatment combination.
• For individuals looking to reduce subcutaneous fat, Caliway Biopharmaceuticals Co., Ltd. is launching NCT07526974, a Phase 3, randomized, double-blinded, placebo-controlled study. This trial, named "SUPREME-02," will evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat in 320 participants.
• Eccogene is initiating the "MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial," NCT07505303. This Phase 2 study, involving 160 participants, will evaluate the effect of oral ECC4703 on body weight reduction and, in a sub-study, on liver fat content.
• In the field of respiratory health, AstraZeneca is sponsoring NCT07525375, a Phase 2 study investigating lung function with two different doses of inhaled glycopyrronium taken with BFF compared to BFF alone in children aged 4 to less than 12 years with asthma. This trial is designed for 69 participants.
• For patients with newly diagnosed amyloid light-chain (AL) amyloidosis, the Case Comprehensive Cancer Center is leading NCT07524634, a Phase 2 study. This research will evaluate the dose schedule of the BCMA Bispecific Antibody, Elranatamab, to determine if it can produce deep remissions and organ recovery in 64 participants.

Expanding Opportunities for Healthy Volunteers

Ohio's research landscape offers significant avenues for individuals without specific health conditions to contribute to medical science. Of the 21 new trials launched this month, 6 are actively seeking healthy volunteers. Statewide, a total of 297 clinical trials are currently recruiting healthy participants, providing numerous opportunities for those interested in supporting medical advancements.

Beyond drug development, new studies are also exploring behavioral interventions and improved access to care. The Children's Hospital Medical Center, Cincinnati is sponsoring NCT07512622, the "Asthma Ctrl SMART Trial," which examines the efficacy of a mobile health adherence intervention for adolescents with asthma. Additionally, a study led by Anny Reyes, NCT07509190, aims to bridge the gap in epilepsy surgery access by educating patients on social determinants of health, involving 310 participants.

Ohio's Diverse Research Footprint: Where to Find Trials

With 3,109 clinical trials currently recruiting across 152 cities and 1,745 research sites, Ohio offers a broad and accessible research environment. This month's new trials demonstrate a strong presence in the state's major metropolitan areas, ensuring that residents in these regions have direct access to new research opportunities. The cities with the most new trials opening in April include:

• Cincinnati (6 new trials)
• Cleveland (6 new trials)
• Columbus (4 new trials)

Other cities with new trials include Canfield, Pickerington, Bay Village, Youngstown, Beachwood, and Canal Winchester, indicating a spread of research activity beyond the largest urban centers.

Eligibility for these new studies is also diverse, ensuring broad participation. Of the new trials, 7 include children, and 16 include older adults, making research accessible across different age groups. No new trials this month are exclusively for female or male participants.

Behind the Science: Sponsors and Study Types

The new trials launched in April are supported by a mix of leading academic institutions and prominent industry sponsors. Academic and institutional sponsors, such as the Ohio State University, Case Western Reserve University, Children's Hospital Medical Center, Cincinnati, and the Case Comprehensive Cancer Center, are driving 14 of the new research initiatives. Industry sponsors, including AstraZeneca, Bial R&D Investments, S.A., Caliway Biopharmaceuticals Co., Ltd., and Incyte Corporation, are behind 7 of the new studies, bringing significant resources to drug and device development.

The types of interventions being studied are varied, reflecting the diverse needs of patients. Drug trials lead the way, accounting for 7 of the new trials. Other categories include device studies, behavioral interventions, and procedures, offering a wide range of participation options for individuals interested in contributing to different facets of medical advancement.

As we move through spring, Ohio's commitment to advancing medical knowledge remains strong, with ongoing opportunities for patients and healthy volunteers to engage with innovative research across a spectrum of health conditions and geographic locations.